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Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody engineering. An ideal production cell line should be highly productive, stable, and deliver an antibody having optimal product quality attributes including minimal protein sequence heterogeneity, maximized functional activities, reproducible glycosylation profile, minimal charge variants, and low potential for aggregation. Cell line development typically involves screening of hundreds to thousands of clones in 96-well plates after stable transfection and gene amplification using DHFR or GS systems. This conventional process is time consuming and often leads to downstream development complexity. In most cases, productivity is the major criterium for clonal selection until a very late stage when only a handful of clones are assessed for the other quality attributes resulting in increased complications and risk. This problem is particularly challenging for cell line development of biosimilar therapeutics because they are required to have the similar biophysical profiles of the innovative products.
To address this need we have developed a proprietary AntibodyMembrane Switch (AMS) technology that facilitates rapid cloning of cell lines for commercial production of antibodies.
AMS technology employs a unique switch mechanism of alternative splicing and site-specific DNA recombinase to turn cells from expressing membrane-anchored antibodies into production cells secreting the antibody. This enables screening of hundreds of millions of cells per day by FACS, permitting selection of highly productive cells with single copy gene integration eliminating the requirement for gene amplification.
AMS technology utilizes an alternative splicing of the immunoglobulin heavy chain CH3 exon fused with transmembrane domain (TM) to display some of the expressed antibodies on the cell surface. The antibody of interest is secreted as well as being anchored on cell surface. Thus the cells can be readily detected and sorted by FACS. The added CH3-TM exon resides in the middle of the intron region between CH2 and CH3 sequences, and is flanked by LoxP, site-specific DNA recombinase Cre recognition sequences. After being selected for high expression levels of membrane-anchored antibodies by FACS using fluorescence-labeled antigen or secondary antibody, the cells are then switched into production cells by providing Cre to remove the CH3-TM exon leaving only a LoxP sequence in the middle of the intron, resulting in a cell line making only secreted antibodies.
Rituxan sequences were cloned into the AMS expression vector with modified introns. Insertion of LoxP in the middle of Intron3 was found to have no effect on antibody expression. Transfection experiments in 293 cells or CHO cells confirmed simultaneous secretion and cell surface expression. Alternative splicing of the CH3 exon was confirmed by RT-PCR and sequencing. Transient transfection of the Cre expressing plasmid switched off expression of the membrane-anchored antibodies.
AMS technology is the most effective and time efficient technology available today for the isolation of production cell lines for therapeutic antibodies or other biological molecules. Utilizing AMS technology can reduce cell line screening time from 6-8 months to 2-3 months. Because AMS generates hundreds to thousands of highly production cell lines, all critical product quality attributes can be assessed at an early stage streamlining downstream process development. 
Proof-of-Concept Experiment
The AMS technology has been used to rapidly generate production CHO cells expressing large quantities of biosimilar antibody Humira. > 200 highly productive clones were generated within 9 weeks. The top 5 clones were grown in FreeStyle CHO Expression Media (Invitrogen) for 7 days in a 50 ml non-fed batch shaking culture. Four of five clones produced more than 300 mg/L of Humira. The top clone produced 752 mg/L of Humira. 
